Evaluating CCS1477 for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study assesses the safety, tolerability, pharmacokinetics, and biological activity of CCS1477 (inobrodib) in patients with various hematological malignancies, including Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, and higher-risk Myelodysplastic Syndrome. It involves patients who have relapsed or refractory conditions and have previously received standard therapies. The study will evaluate the effectiveness of CCS1477 in combination with other treatments such as Pomalidomide and Dexamethasone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provision of consent
* ECOG performance status 0-2
* Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
* Must have previously received standard therapy
* Adequate organ function

Exclusion Criteria:

* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
* Patients should discontinue statins prior to starting study treatment
* CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
* Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
* Any evidence of severe or uncontrolled systemic diseases
* Any known uncontrolled inter-current illness
* QTcF prolongation (\> 470 msec)

Where it's running

• Emory Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting
• Community Health Network
  Indianapolis, Indiana, United States Recruiting
• The Center for Cancer and Blood Disorders (CCBD)
  Bethesda, Maryland, United States Recruiting
• Nebraska Cancer Specialists
  Omaha, Nebraska, United States Recruiting
• University of Nebraska Medical Center
  Omaha, Nebraska, United States Recruiting
• Penn Medicine - Abramson Cancer Center Perelman
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Tim Somervaille — The Christie NHS Foundation Trust
• Study coordinator: Tomasz Knurowski, PhD
• Email: Tomasz.Knurowski@cellcentric.com
• Phone: 07882871299

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.